Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (460)

« Back to Publications

Cerebrospinal fluid proteome alterations related to depressive symptoms in cognitive decline and Alzheimer's disease.

Rabl M. et al, (2025), Alzheimers Dement, 21

Identification of a possible proteomic biomarker in Parkinson's disease: discovery and replication in blood, brain and cerebrospinal fluid.

Winchester L. et al, (2023), Brain Commun, 5

New insights into the genetic etiology of Alzheimer's disease and related dementias.

Bellenguez C. et al, (2022), Nat Genet, 54, 412 - 436

Neurons derived from individual early Alzheimer's disease patients reflect their clinical vulnerability.

Ng B. et al, (2022), Brain Commun, 4

Genome and epigenome wide studies of plasma protein biomarkers for Alzheimer’s disease implicate TBCA and TREM2 in disease risk

Hillary RF. et al, (2021)

NMerge: A comprehensive and accessible Alzheimer’s disease patient-level dataset

Birkenbihl C. et al, (2020)

Tau pathology in early Alzheimer's disease is linked to selective disruptions in neurophysiological network dynamics.

Kocagoncu E. et al, (2020), Neurobiol Aging, 92, 141 - 152

Dysregulated Fc gamma receptor-mediated phagocytosis pathway in Alzheimer's disease: network-based gene expression analysis.

Park YH. et al, (2020), Neurobiol Aging, 88, 24 - 32

Minocycline 200 mg or 400 mg versus placebo for mild Alzheimer’s disease: the MADE Phase II, three-arm RCT

Howard R. et al, (2020), Efficacy and Mechanism Evaluation, 7, 1 - 62

Minocycline at 2 Different Dosages vs Placebo for Patients With Mild Alzheimer Disease: A Randomized Clinical Trial.

Howard R. et al, (2020), JAMA Neurol, 77, 164 - 174

Will We Have a Drug for Alzheimer's Disease by 2030? The View From Pharma.

Lovestone S. and Manji HK., (2020), Clin Pharmacol Ther, 107, 79 - 81

Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort.

Westwood S. et al, (2020), J Alzheimers Dis, 74, 213 - 225

Genetic and Real-World Clinical Data, Combined with Empirical Validation, Nominate Jak-Stat Signaling as a Target for Alzheimer's Disease Therapeutic Development.

Nevado-Holgado AJ. et al, (2019), Cells, 8

Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum.

Bos I. et al, (2019), Alzheimers Dement, 15, 644 - 654

plasma protein classifier for predicting amyloid burden for preclinical Alzheimer's disease.

Ashton NJ. et al, (2019), Sci Adv, 5

Load More

1
2
3
4
5
6
7
...
»